Michele Pozzoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michele Pozzoli has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Paul Michael Young
Respiratory Technology, The Woolcock Institute of Medical Research, Glebe, Sydney, NSW 2037, Australia
12 shared publications - Daniela Traini
Respiratory Technology, Woolcock Institute of Medical Research, Sydney, Australia; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Australia
11 shared publications - Fabio Sonvico
University of Parma
6 shared publications - Hui Xin Ong
Macquarie University
6 shared publications - Arianna Fallacara
Department of Life Sciences and Biotechnology, Master Course in Cosmetic Science and Technology (COSMAST), University of Ferrara, Via L. Borsari 46, 44121 Ferrara, Italy
3 shared publications - Gabriela Garrastazu Pereira
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil
3 shared publications
Latest Publications
- Open Access
- 1 July 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 902, 174098
Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line
- 1 July 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 902, 174098
Open AccessTobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line
- 1 November 2020
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 156, 121-130
An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line
- 1 November 2020
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 156, 121-130
An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line
- 3 September 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (7) , 299
Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds
The integrity of the nasal epithelium plays a crucial role in the airway defence mechanism. The nasal epithelium may be injured as a result of a large number of factors leading to nose bleeds, also...
- 3 September 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (7) , 299
Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds
The integrity of the nasal epithelium plays a crucial role in the airway defence mechanism. The nasal epithelium may be injured as a result of a large number of factors leading to nose bleeds, also...
- 1 September 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (9) , 2964-2971
Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation
- 1 September 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (9) , 2964-2971
Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation
- 3 April 2019
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 16 (4) , 453-466
Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders
Background: The in-situ gelation of thermosensitive nasal formulations with desirable spray characteristics at room temperature and ability to undergo a phase change to a semi-solid state with mucoadhesive behaviour at physiological temperature has the potential to efficiently deliver therapeutics to brain. Although such thermosensitive polymeric nasal formulations have been well studied in the literature for their thermogelling properties, their application in nasal spray generation with favourable characteristics has not been investigated. Methods: Thermosensitive chitosan (CS)-based formulations with different viscosities were prepared for intranasal delivery of ibuprofen using CS of various molecular weights. The formulation developed was optimized with regards to its physicochemical, rheological, biological properties and the generated aerosol characteristics. Results: The formulations showed rapid gelation (4 – 7 min) at 30 – 35°C, which lies in the human nasal cavity temperature spectrum. The decrease in CS molecular weight to 110 – 150 kDa led to generation of optimum spray with lower Dv50, wider spray area, and higher surface area coverage. This formulation also showed improved ibuprofen solubility that is approximately 100X higher than its intrinsic aqueous solubility, accelerated ibuprofen transport across human nasal epithelial cells and transient modulation of tight junctions. Conclusions: A thermosensitive CS-based formulation has been successfully developed with suitable rheological properties, aerosol performance and biological properties that is beneficial for nose-to-brain drug delivery.
- 3 April 2019
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 16 (4) , 453-466
Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders
Background: The in-situ gelation of thermosensitive nasal formulations with desirable spray characteristics at room temperature and ability to undergo a phase change to a semi-solid state with mucoadhesive behaviour at physiological temperature has the potential to efficiently deliver therapeutics to brain. Although such thermosensitive polymeric nasal formulations have been well studied in the literature for their thermogelling properties, their application in nasal spray generation with favourable characteristics has not been investigated. Methods: Thermosensitive chitosan (CS)-based formulations with different viscosities were prepared for intranasal delivery of ibuprofen using CS of various molecular weights. The formulation developed was optimized with regards to its physicochemical, rheological, biological properties and the generated aerosol characteristics. Results: The formulations showed rapid gelation (4 – 7 min) at 30 – 35°C, which lies in the human nasal cavity temperature spectrum. The decrease in CS molecular weight to 110 – 150 kDa led to generation of optimum spray with lower Dv50, wider spray area, and higher surface area coverage. This formulation also showed improved ibuprofen solubility that is approximately 100X higher than its intrinsic aqueous solubility, accelerated ibuprofen transport across human nasal epithelial cells and transient modulation of tight junctions. Conclusions: A thermosensitive CS-based formulation has been successfully developed with suitable rheological properties, aerosol performance and biological properties that is beneficial for nose-to-brain drug delivery.
- Open Access
- 1 December 2018
- Published by MDPI AG in Pharmaceutics
- Vol. 10 (4) , 254
Formulation and Characterization of Native and Crosslinked Hyaluronic Acid Microspheres for Dermal Delivery of Sodium Ascorbyl Phosphate: A Comparative Study
The present work evaluates for the first time the use of urea-crosslinked hyaluronic acid (HA-CL), a novel derivative of native hyaluronic acid (HA), to produce microspheres (MS) by emulsification-solvent evaporation, for dermal delivery of sodium ascorbyl phosphate (SAP). As the term of comparison, HA MS were prepared. A pre-formulation study—investigation of the effects of polymers solutions properties (pH, viscosity) and working conditions—led to the production of optimized HA-CL MS and HA-CL—SAP MS with: almost unimodal size distributions; mean diameter of 13.0 ± 0.7 and 9.9 ± 0.8 µm, respectively; spherical shape and rough surface; high yield, similar to HA MS and HA–SAP MS (≈ 85%). SAP was more efficiently encapsulated into HA-CL MS (78.8 ± 2.6%) compared to HA MS (69.7 ± 4.6%). Physical state, thermal properties, relative moisture stability of HA-CL MS and HA-CL–SAP MS were comparable to those of HA MS and HA–SAP MS. However, HA-CL–SAP MS exhibited an extended drug release compared to HA–SAP MS, despite the same kinetic mechanism—contemporaneous drug diffusion and polymer swelling/dissolution. Therefore, HA-CL formulation showed a greater potential as microcarrier (for encapsulation efficiency and release kinetic), that could be improved, in future, using suitable excipients.
- 1 December 2018
- Published by MDPI AG in Pharmaceutics
- Vol. 10 (4) , 254
Open AccessFormulation and Characterization of Native and Crosslinked Hyaluronic Acid Microspheres for Dermal Delivery of Sodium Ascorbyl Phosphate: A Comparative Study
The present work evaluates for the first time the use of urea-crosslinked hyaluronic acid (HA-CL), a novel derivative of native hyaluronic acid (HA), to produce microspheres (MS) by emulsification-solvent evaporation, for dermal delivery of sodium ascorbyl phosphate (SAP). As the term of comparison, HA MS were prepared. A pre-formulation study—investigation of the effects of polymers solutions properties (pH, viscosity) and working conditions—led to the production of optimized HA-CL MS and HA-CL—SAP MS with: almost unimodal size distributions; mean diameter of 13.0 ± 0.7 and 9.9 ± 0.8 µm, respectively; spherical shape and rough surface; high yield, similar to HA MS and HA–SAP MS (≈ 85%). SAP was more efficiently encapsulated into HA-CL MS (78.8 ± 2.6%) compared to HA MS (69.7 ± 4.6%). Physical state, thermal properties, relative moisture stability of HA-CL MS and HA-CL–SAP MS were comparable to those of HA MS and HA–SAP MS. However, HA-CL–SAP MS exhibited an extended drug release compared to HA–SAP MS, despite the same kinetic mechanism—contemporaneous drug diffusion and polymer swelling/dissolution. Therefore, HA-CL formulation showed a greater potential as microcarrier (for encapsulation efficiency and release kinetic), that could be improved, in future, using suitable excipients.
- Open Access
- 13 October 2018
- Published by MDPI AG in Nanomaterials
- Vol. 8 (10) , 825
Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω-3 Fatty Acid Derivatives
Lipid-based drugs are emerging as an interesting class of novel anticancer drugs with the potential to target specific cancer cell metabolic pathways linked to their proliferation and invasiveness. In particular, ω-3 polyunsaturated fatty acids (PUFA) derivatives such as epoxides and their bioisosteres have demonstrated the potential to suppress growth and promote apoptosis in triple-negative human breast cancer cells MDA-MB-231. In this study, 16-(4′-chloro-3′-trifluorophenyl)carbamoylamino]hexadecanoic acid (ClFPh-CHA), an anticancer lipid derived from ω-3,17,18-epoxyeicosanoic acid, was formulated as a stable nanoemulsion with size around 150 nm and narrow droplet size distribution (PDI < 0.200) through phase-inversion emulsification process followed by high pressure homogenization in view of an oral administration. The ClFPh-CHA-loaded nanoemulsions were able to significantly decrease the relative tumor volume in mice bearing an intramammary tumor xenograft at all doses tested (2.5, 10 and 40 mg/kg) after 32 days of daily oral administration. Furthermore, absolute tumor weight was decreased to 50% of untreated control at 10 and 40 mg/kg, while intraperitoneal administration could achieve a significant reduction only at the highest dose of 40 mg/kg. Results suggest that oral administration of ClFPh-CHA formulated as a nanoemulsion has a sufficient bioavailability to provide an anticancer effect in mice and that the activity is at least equal if not superior to that obtained by a conventional parenteral administration of equivalent doses of the same drug.
- 13 October 2018
- Published by MDPI AG in Nanomaterials
- Vol. 8 (10) , 825
Open AccessNanoemulsion-Enabled Oral Delivery of Novel Anticancer ω-3 Fatty Acid Derivatives
Lipid-based drugs are emerging as an interesting class of novel anticancer drugs with the potential to target specific cancer cell metabolic pathways linked to their proliferation and invasiveness. In particular, ω-3 polyunsaturated fatty acids (PUFA) derivatives such as epoxides and their bioisosteres have demonstrated the potential to suppress growth and promote apoptosis in triple-negative human breast cancer cells MDA-MB-231. In this study, 16-(4′-chloro-3′-trifluorophenyl)carbamoylamino]hexadecanoic acid (ClFPh-CHA), an anticancer lipid derived from ω-3,17,18-epoxyeicosanoic acid, was formulated as a stable nanoemulsion with size around 150 nm and narrow droplet size distribution (PDI < 0.200) through phase-inversion emulsification process followed by high pressure homogenization in view of an oral administration. The ClFPh-CHA-loaded nanoemulsions were able to significantly decrease the relative tumor volume in mice bearing an intramammary tumor xenograft at all doses tested (2.5, 10 and 40 mg/kg) after 32 days of daily oral administration. Furthermore, absolute tumor weight was decreased to 50% of untreated control at 10 and 40 mg/kg, while intraperitoneal administration could achieve a significant reduction only at the highest dose of 40 mg/kg. Results suggest that oral administration of ClFPh-CHA formulated as a nanoemulsion has a sufficient bioavailability to provide an anticancer effect in mice and that the activity is at least equal if not superior to that obtained by a conventional parenteral administration of equivalent doses of the same drug.
- 28 November 2017
- Published by Taylor & Francis in Expert Opinion on Orphan Drugs
- Vol. 6 (1) , 69-84
Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
Introduction: Cystic fibrosis (CF) is a congenital life-limiting, orphan disease affecting 1/2500 – 1/3000 people worldwide with the greatest prevalence in Europe, North America and Australia. The primary reason underpinning the cause of morbidity and mortality of CF patients is associated with recurrent pulmonary inflammation and infection that leads to chronic, progressive lung deterioration and ultimately death of CF patients. Areas covered: This review aims to explore the potential role for inhaled anti-inflammatory drugs as a more successful treatment option for CF, in comparison with current oral delivery. Specifically, the focus is on ibuprofen, the only nonsteroidal anti-inflammatory drug approved for chronic use in CF. The need for inhalation therapy has also been highlighted with an insight on the reasons and challenges associated with developing an inhalation therapy of nonsteroidal anti-inflammatory drugs (NSAIDs). Expert opinion: There is a fundamental need to direct research towards development of anti-inflammatory drugs to control inflammation rather than just targeting infection. Development of an inhalable preparation of ibuprofen alone or in combination with an antibiotic holds the potential to be the most effective treatment option among the existing array of therapies available for CF.
- 28 November 2017
- Published by Taylor & Francis in Expert Opinion on Orphan Drugs
- Vol. 6 (1) , 69-84
Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
Introduction: Cystic fibrosis (CF) is a congenital life-limiting, orphan disease affecting 1/2500 – 1/3000 people worldwide with the greatest prevalence in Europe, North America and Australia. The primary reason underpinning the cause of morbidity and mortality of CF patients is associated with recurrent pulmonary inflammation and infection that leads to chronic, progressive lung deterioration and ultimately death of CF patients. Areas covered: This review aims to explore the potential role for inhaled anti-inflammatory drugs as a more successful treatment option for CF, in comparison with current oral delivery. Specifically, the focus is on ibuprofen, the only nonsteroidal anti-inflammatory drug approved for chronic use in CF. The need for inhalation therapy has also been highlighted with an insight on the reasons and challenges associated with developing an inhalation therapy of nonsteroidal anti-inflammatory drugs (NSAIDs). Expert opinion: There is a fundamental need to direct research towards development of anti-inflammatory drugs to control inflammation rather than just targeting infection. Development of an inhalable preparation of ibuprofen alone or in combination with an antibiotic holds the potential to be the most effective treatment option among the existing array of therapies available for CF.